Binds Microorganism Or Normal Or Mutant Component Or Product Thereof (e.g., Animal Cell, Cell-surface Antigen, Secretory Product, Etc.) Patents (Class 530/388.2)
  • Patent number: 10364284
    Abstract: Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 30, 2019
    Assignee: Eisai, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Patent number: 9895441
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: February 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Heather Maecker, Bryan Irving
  • Patent number: 9879221
    Abstract: An IVF system for successfully utilizing spermatozoa separated into X-chromosome bearing and into Y-chromosome bearing population for insemination. The IVF system includes fertilization medium that can shorten the time from insemination to cleavage and a portable incubator for the transportation of maturing oocytes and inseminated oocytes comprising a straw (19) and an incubation element (20) that can be sealed with a cap (22).
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 30, 2018
    Assignee: XY, LLC
    Inventors: George E. Seidel, Tae Kwang Suh, Kehuan Lu
  • Patent number: 9068006
    Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: June 30, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Jose A. Halperin, Michael Chorev
  • Patent number: 9028826
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Dartmouth College
    Inventor: Randolph J. Noelle
  • Patent number: 9000133
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: April 7, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • Publication number: 20150086572
    Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 26, 2015
    Inventors: Michael Fung, Meisheng Lu, William N.C. Sun, Cecily R.Y. Sun
  • Patent number: 8980821
    Abstract: A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: March 17, 2015
    Assignee: Herantis Pharma Oyj
    Inventors: Mart Saarma, Juha Lauren, Päivi Lindholm, Tonis Timmusk, Raimo Tuominen
  • Patent number: 8975036
    Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: March 10, 2015
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
  • Patent number: 8968740
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 3, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Patent number: 8962806
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: February 24, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's Hospital
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Patent number: 8961976
    Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 24, 2015
    Assignee: Biogen Idec Ma Inc.
    Inventors: Herman Van Vlijmen, Alexey Lugovskoy, Karl Hanf
  • Patent number: 8956607
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ?(IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: February 17, 2015
    Assignee: Biotest AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
  • Patent number: 8945564
    Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: February 3, 2015
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Xiaofeng Lu, Bao-Lu Chen, Kidisti Araya, Augustus Okhamafe
  • Patent number: 8945565
    Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: February 3, 2015
    Assignees: Selexys Pharmaceuticals Corporation, Oklahoma Medical Research Foundation
    Inventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
  • Patent number: 8945562
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: February 3, 2015
    Assignee: True North Therapeutics, Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 8940304
    Abstract: The present invention relates to monoclonal antibodies capable of recognizing and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant Staphylococcus Aureus (MRSA), coagulase-negative Staphilococcus, Staphylococcus sciuri and Enterococcus, and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognizing and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: January 27, 2015
    Assignee: Fundaco Oswaldo Cruz
    Inventors: Jose Procopio Moreno Senna, Joao Luiz Sampaio Queiroz, Nadia Maria Batoreu, Maria da Gloria Martins Teixeira
  • Publication number: 20150018531
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 15, 2015
    Applicant: STEM CENTRX, INC.
    Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
  • Patent number: 8926979
    Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: January 6, 2015
    Assignees: Novartis AG, XOMA Technology Ltd.
    Inventors: Sharon Lea Aukerman, Mohammad Luqman
  • Publication number: 20150005475
    Abstract: The disclosure provides a method of reducing aggregates in a preparation of monoclonal antibody by modifying at least three parameters in the bioreactor culture process.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 1, 2015
    Applicant: MEDIMMUNE LIMITED
    Inventors: Justyna Kucia, Marcel Kuiper, Richard Tran, David Gruber
  • Patent number: 8911726
    Abstract: A highly stable mutant of human IgG4 antibody is provided. Such antibody is an antibody in which the CH3 domain of human IgG4 is substituted with the CH3 domain of human IgG1 and which exhibits inhibited aggregate formation, an antibody in which the CH3 and CH2 domains of human IgG4 are substituted with the CH3 and CH2 domains of human IgG1, respectively, or an antibody in which arginine at position 409 indicated in the EU index proposed by Kabat et al. of human IgG4 is substituted with lysine and which exhibits inhibited aggregate formation.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: December 16, 2014
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Nobuaki Takahashi, Hideaki Yoshida
  • Publication number: 20140363447
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 11, 2014
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Publication number: 20140363436
    Abstract: Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 11, 2014
    Inventors: Hitoshi Suzuki, Run Fan, Bruce A. Julian, Jan Novak, Zina Moldoveanu, Zhixin Zhang, Milan Tomana, Jiri Mestecky, Robert J. Wyatt, Yasuhiko Tomino, Yusuke Suzuki, Stephen Olson
  • Publication number: 20140357517
    Abstract: The present disclosure provides a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein and a kit for radiation exposure diagnosis. Methods of diagnosing radiation exposure as well as methods for screening an agent for enhancing radiation sensitivity or for radiation protection are disclosed. Also provided are compositions for enhancing radiation sensitivity and/or radiation protection.
    Type: Application
    Filed: May 9, 2012
    Publication date: December 4, 2014
    Applicant: Korea Institute of Radiological & Medical Sciences
    Inventors: Kwang Seok Kim, Sang Woo Bae, Kyu Jin Choi, Eun Sook Kim
  • Patent number: 8901282
    Abstract: The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: December 2, 2014
    Assignee: Rappaport Family Institute for Research in the Medical Sciences
    Inventors: Jacob Victor, Noah Berkowitz, Andrew Levy
  • Patent number: 8901280
    Abstract: The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: December 2, 2014
    Assignee: Gene Techno Science Co., Ltd.
    Inventors: Shigeyuki Kon, Chiemi Kimura, Toshimitsu Uede
  • Patent number: 8900586
    Abstract: The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and/or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: December 2, 2014
    Assignees: Dinona Inc., SNU R&DB Foundation
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • Patent number: 8895010
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: November 25, 2014
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Patent number: 8895704
    Abstract: Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: November 25, 2014
    Assignee: Morphotek, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Patent number: 8889846
    Abstract: This invention provides antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: November 18, 2014
    Assignee: Morphotek, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Patent number: 8889833
    Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 18, 2014
    Assignee: Incyte Corporation
    Inventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Elliott Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
  • Patent number: 8889138
    Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: November 18, 2014
    Assignees: Merck Sharp & Dohme Corp., Northwestern University
    Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
  • Patent number: 8877197
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: November 4, 2014
    Assignee: True North Therapeutics, Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 8865875
    Abstract: The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: October 21, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Jie Liu, David King
  • Patent number: 8852597
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: October 7, 2014
    Assignee: The Trustees of Dartmouth College
    Inventor: Randolph J. Noelle
  • Publication number: 20140295463
    Abstract: The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans.
    Type: Application
    Filed: April 22, 2014
    Publication date: October 2, 2014
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Antara Datta, Jason Trama
  • Patent number: 8846045
    Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: September 30, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Kristian Kjaergaard, Soeren Lund
  • Patent number: 8828396
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: September 9, 2014
    Assignee: Novartis AG
    Inventors: Christoph Heusser, James Rush, Karen Vincent
  • Patent number: 8828397
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: September 9, 2014
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • Publication number: 20140248297
    Abstract: The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or non-response of pretested populations of subjects.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 4, 2014
    Applicant: NOVARX CORPORATION
    Inventors: Habib Fakhrai, Daniel L. Shawler
  • Publication number: 20140249298
    Abstract: This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENT1 expression and/or activity.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 4, 2014
    Inventors: Marit Liland Sandvold, Finn Myhren, Carol Cass, James Young
  • Patent number: 8822168
    Abstract: The present invention includes assays and kits for detecting the assembly of an RNA binding protein-RNA complex and for detecting the activity of an RNA binding protein.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 2, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Lili Wan, Elizabeth Ottinger
  • Patent number: 8821880
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: September 2, 2014
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Patent number: 8821856
    Abstract: Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: September 2, 2014
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Pin Wang, Lili Yang
  • Publication number: 20140241984
    Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.
    Type: Application
    Filed: December 23, 2013
    Publication date: August 28, 2014
    Applicant: UNITED ARAB EMIRATES UNIVERSITY
    Inventor: OMAR EL-AGNAF
  • Publication number: 20140242072
    Abstract: The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 28, 2014
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventor: Markus Hansson
  • Patent number: 8808701
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 19, 2014
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • Patent number: 8802096
    Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
    Type: Grant
    Filed: November 26, 2010
    Date of Patent: August 12, 2014
    Assignee: Inflarx GmbH
    Inventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
  • Patent number: 8778345
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: July 15, 2014
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 8765131
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: July 1, 2014
    Assignee: Genentech, Inc.
    Inventors: Michael Fung, William N. C. Sun, Cecily R. Y. Sun